<DOC>
	<DOCNO>NCT02403648</DOCNO>
	<brief_summary>BIOD-961 dry powder formulation glucagon intend use device mix ( reconstitutes ) powder liquid make easy user treat patient severe hypoglycemia . The purpose study evaluate much BIOD-961 absorbs bloodstream , much raise glucose concentration ( intended effect ) compare two glucagon product already market .</brief_summary>
	<brief_title>Pharmacokinetics Pharmacodynamics BIOD-961 v . Marketed Glucagons</brief_title>
	<detailed_description>Subjects receive separate day , random order one following : 1 mg BIOD-961 intramuscularly ( IM ) , 1 mg Lilly ( IM ) , 1 mg Novo ( IM ) , 1 mg BIOD-961 subcutaneously ( SC ) , 1 mg Lilly ( SC ) , 1 mg Novo ( SC ) .</detailed_description>
	<mesh_term>Hypoglycemia</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>Body Mass Index : 18.525.0 kg/m2 inclusive . Subject provide informed consent sign date informed consent form trialrelated activity . Type 1 type 2 diabetes mellitus . History pheochromocytoma , insulinoma , glucagonoma , glycogen storage disease . History regular alcohol consumption define alcohol intake exceed 7 drink per week female 14 drink per week male , 1 drink = 5 ounce wine 12 ounce beer 1.5 ounce hard liquor . Significant cardiovascular ( include New York Heart Association ( NYHA ) Class III IV functional capacity uncontrolled hypertension ) , respiratory , gastrointestinal , hepatic , renal , neurological , psychiatric and/or hematological disease . Any significant cardiovascular event history , include angina , myocardial infarction , therapeutic coronary procedure ( e.g , percutaneous transluminal coronary angioplasty , coronary bypass surgery ) , stroke , transient ischemic attack . Females breast feeding , pregnant , intend become pregnant study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>